NCT06726720 UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
| NCT ID | NCT06726720 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-12-16 |
| Primary Completion | 2032-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-12-16 with a primary completion date of 2032-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in combination at any stage of disease. Three cohorts are designed, based on the stage of NSCLC (resectable, unresectable and metastatic). The multicohort study is modular in design. Specific modules will be set up separately to assess each new indication of drugs developed by AZ or as part of an AZ alliance once European marketing authorization (MA) has been granted and made available in the participating countries. Patients will be enrolled in the study if they have received (retrospective), receive (retrospective and prospective) or will receive (prospective) approved drugs developed by AZ or as part of an AZ alliance according to the eligibility criteria. Treatment plan and decision are made independently by each treating physician prior to inclusion in this study.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years old) * Patients with histologically or cytologically proven NSCLC * Patients initiated with approved drugs developed by AZ or as part of an AZ alliance at the time of the enrollment or within the previous three weeks. * Informed patients who consent to participate in the study as per local regulations. Exclusion Criteria: * Patients participating in an interventional clinical trial for NSCLC\* \* with the exception on low-interventional studies (RIPH2) where the intervention does not involve the NSCLC treatment * Patients already enrolled in another module of the cohort in UMBREALUNG * Patients under safeguard of justice, curatorship or guardianship
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06726720 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06726720 currently recruiting?
Yes, NCT06726720 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06726720 trial being conducted?
This trial is being conducted at Aix-en-Provence, France, Angers, France, Aurillac, France, Auxerre, France and 11 additional locations.
Who is sponsoring the NCT06726720 clinical trial?
NCT06726720 is sponsored by AstraZeneca. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.